Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer.

Fernandez HR, Gadre SM, Tan M, Graham GT, Mosaoa R, Ongkeko MS, Kim KA, Riggins RB, Parasido E, Petrini I, Pacini S, Cheema A, Varghese R, Ressom HW, Zhang Y, Albanese C, Üren A, Paige M, Giaccone G, Avantaggiati ML.

Cell Death Differ. 2018 Jul;25(7):1239-1258. doi: 10.1038/s41418-018-0101-z. Epub 2018 Apr 12.

2.

EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer.

Singh S, Trevino J, Bora-Singhal N, Coppola D, Haura E, Altiok S, Chellappan SP.

Mol Cancer. 2012 Sep 25;11:73. doi: 10.1186/1476-4598-11-73.

3.

Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor.

Murakami A, Takahashi F, Nurwidya F, Kobayashi I, Minakata K, Hashimoto M, Nara T, Kato M, Tajima K, Shimada N, Iwakami S, Moriyama M, Moriyama H, Koizumi F, Takahashi K.

PLoS One. 2014 Jan 28;9(1):e86459. doi: 10.1371/journal.pone.0086459. eCollection 2014.

4.

Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.

Corominas-Faja B, Oliveras-Ferraros C, Cuyàs E, Segura-Carretero A, Joven J, Martin-Castillo B, Barrajón-Catalán E, Micol V, Bosch-Barrera J, Menendez JA.

Cell Cycle. 2013 Nov 1;12(21):3390-404. doi: 10.4161/cc.26417. Epub 2013 Sep 17.

5.

The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer.

Suresh R, Ali S, Ahmad A, Philip PA, Sarkar FH.

Adv Exp Med Biol. 2016;890:57-74. doi: 10.1007/978-3-319-24932-2_4. Review.

PMID:
26703799
6.

Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.

Sette G, Salvati V, Mottolese M, Visca P, Gallo E, Fecchi K, Pilozzi E, Duranti E, Policicchio E, Tartaglia M, Milella M, De Maria R, Eramo A.

Cell Death Dis. 2015 Aug 6;6:e1850. doi: 10.1038/cddis.2015.217.

7.

Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.

Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz E, Caserini R, Lo Vullo S, Camerini T, Mariani L, Delia D, Calabrò E, Pastorino U, Sozzi G.

Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16281-6. doi: 10.1073/pnas.0905653106. Epub 2009 Sep 10.

8.
9.

Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI.

Weng CH, Chen LY, Lin YC, Shih JY, Lin YC, Tseng RY, Chiu AC, Yeh YH, Liu C, Lin YT, Fang JM, Chen CC.

Oncogene. 2019 Jan;38(4):455-468. doi: 10.1038/s41388-018-0454-2. Epub 2018 Aug 15.

PMID:
30111817
10.

Cancer stem cells and cisplatin-resistant cells isolated from non-small-lung cancer cell lines constitute related cell populations.

Lopez-Ayllon BD, Moncho-Amor V, Abarrategi A, Ibañez de Cáceres I, Castro-Carpeño J, Belda-Iniesta C, Perona R, Sastre L.

Cancer Med. 2014 Oct;3(5):1099-111. doi: 10.1002/cam4.291. Epub 2014 Jun 25.

11.

Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.

Kobayashi I, Takahashi F, Nurwidya F, Nara T, Hashimoto M, Murakami A, Yagishita S, Tajima K, Hidayat M, Shimada N, Suina K, Yoshioka Y, Sasaki S, Moriyama M, Moriyama H, Takahashi K.

Biochem Biophys Res Commun. 2016 Apr 22;473(1):125-132. doi: 10.1016/j.bbrc.2016.03.064. Epub 2016 Mar 17.

PMID:
26996130
12.

Sulforaphane inhibits cancer stem-like cell properties and cisplatin resistance through miR-214-mediated downregulation of c-MYC in non-small cell lung cancer.

Li QQ, Xie YK, Wu Y, Li LL, Liu Y, Miao XB, Liu QZ, Yao KT, Xiao GH.

Oncotarget. 2017 Feb 14;8(7):12067-12080. doi: 10.18632/oncotarget.14512.

13.

Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.

Wang L, Liu X, Ren Y, Zhang J, Chen J, Zhou W, Guo W, Wang X, Chen H, Li M, Yuan X, Zhang X, Yang J, Wu C.

Cell Death Dis. 2017 Apr 13;8(4):e2746. doi: 10.1038/cddis.2016.409.

14.

Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.

Shou J, You L, Yao J, Xie J, Jing J, Jing Z, Jiang L, Sui X, Pan H, Han W.

Cancer Lett. 2016 Aug 28;379(1):124-33. doi: 10.1016/j.canlet.2016.06.002. Epub 2016 Jun 2.

PMID:
27264264
15.

EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer.

Cheng CC, Chou KF, Wu CW, Su NW, Peng CL, Su YW, Chang J, Ho AS, Lin HC, Chen CG, Yang BL, Chang YC, Chiang YW, Lim KH, Chang YF.

Lung Cancer. 2018 Feb;116:80-89. doi: 10.1016/j.lungcan.2017.12.017. Epub 2017 Dec 29.

PMID:
29413056
16.

NEAT1 contributes to the CSC-like traits of A549/CDDP cells via activating Wnt signaling pathway.

Jiang P, Xu H, Xu C, Chen A, Chen L, Zhou M, Haq IU, Wu X, Mariyam Z, Feng Q.

Chem Biol Interact. 2018 Dec 25;296:154-161. doi: 10.1016/j.cbi.2018.10.001. Epub 2018 Oct 3.

PMID:
30291867
17.

244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.

Zhang Y, Yao K, Shi C, Jiang Y, Liu K, Zhao S, Chen H, Reddy K, Zhang C, Chang X, Ryu J, Bode AM, Dong Z, Dong Z.

Oncotarget. 2015 Dec 29;6(42):44274-88. doi: 10.18632/oncotarget.6236.

18.

Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.

Xie M, He CS, Wei SH, Zhang L.

Eur J Cancer. 2013 Nov;49(16):3559-72. doi: 10.1016/j.ejca.2013.07.007. Epub 2013 Aug 2.

PMID:
23916913
19.

Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation.

Leung EL, Fan XX, Wong MP, Jiang ZH, Liu ZQ, Yao XJ, Lu LL, Zhou YL, Yau LF, Tin VP, Liu L.

Antioxid Redox Signal. 2016 Feb 10;24(5):263-79. doi: 10.1089/ars.2015.6420. Epub 2015 Dec 14.

20.

Human non-small cell lung cancer expresses putative cancer stem cell markers and exhibits the transcriptomic profile of multipotent cells.

Zakaria N, Yusoff NM, Zakaria Z, Lim MN, Baharuddin PJ, Fakiruddin KS, Yahaya B.

BMC Cancer. 2015 Feb 25;15:84. doi: 10.1186/s12885-015-1086-3.

Supplemental Content

Support Center